Article
Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3.
Alimentary pharmacology & therapeutics - 1 Jan 2018
Younossi Z M, Stepanova M, Jacobson I M, Asselah T, Gane E J, Lawitz E, Foster G R, Roberts S K, Thompson A J, Willems B E, Welzel T M, Pearlman B, Younossi I, Racila A, Henry L
Abstract excerpt
BACKGROUND: Chronic hepatitis C infection leads to impairment of patient-reported outcomes (PROs). Treatment with direct-acting antiviral regimens results in short- and long-term improvement of these outcomes. AIM: To assess PROs in patients treated with a newly developed direct-acting antiviral, a fixed-dose combination of sofosbuvir/velpatasvir (SOF/VEL) with/without voxilaprevir (VOX). METHODS: The PRO data...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.